NSE:MANGALAM
MANGALAM DRUG & CHEM LTD
Healthcare › Pharmaceuticals & Biotechnology
₹32.94
at close · 21 Sept 2026
Latest filings
- Bank loan default disclosed: about Rs 15.57 crore overdue across two lenders · Credit & Debt
- Appointment of Mr. Prabhakar Raghunath Zavar as Independent Director for 5 years · Management Changes
- Board appoints Prabhakar Zavar as Independent Director for 5 years · Management Changes
- Mangalam Drugs announces 53rd AGM on September 23, 2026 via video conferencing · Compliance
- 53rd AGM on Sept 23, 2026 via VC; annual report dispatched electronically · Compliance
- Mangalam Drugs 53rd AGM on Sep 23, 2026; annual report and notice filed · Board & Shareholder Meetings
- Default on bank loans exceeds 30 days across two lenders · Credit & Debt
- Newspaper publication of Q1 FY27 unaudited financial results · Compliance
- Board approves Q1 FY27 results, appoints Statutory and Secretarial Auditors for 5 years · Management Changes
- Q1 FY27 Results: Net Loss Narrows to Rs 7.55 Cr vs Rs 13.73 Cr YoY · Results
- Q1FY27 Results: Loss Narrows to Rs 7.55 Cr; New Auditors Appointed · Results
- Secretarial Auditor resigns citing pre-occupancy · Management Changes
- Board meeting on Aug 12 for Q1 FY27 results and auditor changes · Board & Shareholder Meetings
- Default on bank loans: Rs 15.57 cr overdue to Bank of Baroda and Bank of Maharashtra · Credit & Debt
- Mangalam Drugs defaults on bank loans; about Rs 15.57 cr overdue to BoB and BoM · Credit & Debt
- Quarterly RTA compliance certificate filed under SEBI Reg 74(5) · Compliance
- Trading Window Closed from July 1 for Q1 FY27 Results · Compliance
- Trading window closes from July 1 ahead of Q1 results · Compliance
- Re-appointment of Independent Director approved via Postal Ballot · Management Changes
- Postal ballot results: re-appointment of Mr Praveen Saxena as Independent Director · Management Changes
- Defaults on bank loans worth Rs 15.58 crores, exceeds 30 days · Regulatory & Legal
- Promoter confirms no new encumbrances created in FY25-26 · Ownership Changes
- Submission of Annual Secretarial Compliance Report for the period ended 31st March, 2026 · Compliance
- Annual Secretarial Compliance Report to be filed for the financial year ended March 31, 2026 as per Regulation 24A of SEBI LODR, 2025. · Compliance
- Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Disclosure under Regulation 30 of LODR 2015 for newspaper publication regarding the dispatch of Postal Ballot/ E- Voting seeking shareholders approval. · Compliance
- Mangalam Drugs And Organics Limited has informed the Exchange regarding Notice of Postal Ballot · Board & Shareholder Meetings
- Disclosure of notice of postal ballot /E- Voting seeking shareholders approval pursuant to Regulation 30 of SEBI LODR, 2015 . for reappointment of Shri Praveen Saxena as an Independent .... · Management Changes
- Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest · Credit & Debt
- Intimation of subsequent default of Bank under Para A sub-paragraph 6 of Schedule III-Subsequent default · Credit & Debt
- Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Newspaper Publication for declaration of Annual Financial Results (Consolidated and Standalone) for the quarter and financial year ended March 31, 2026. · Compliance
- Approval of Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026 · Results
- Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
- Declaration of Financial Results ( Consolidated and Standalone) for the quarter and year ended March 31, 2026 · Results
- Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
- Outcome of Board Meeting held on 14th May 2026 for declaration of Audited Financial Results (Standalone & Consolidated) of the Company for the period ended 31st, March, 2026 · Results
- Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Intimation of Board .... · Board & Shareholder Meetings
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Shree Kishoriju .... · Ownership Changes
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Shree Rasbihari .... · Ownership Changes
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 29, 2026 for Aditya Ramniwas Dhoot · Ownership Changes
- Shree Kishoriju Trading and Investments Pvt Ltd has submitted to the Exchange a copy of Disclosure under Regulations 31(1) and 31(2) of the SEBI (SAST) Regulations, 2011/ · Ownership Changes
- Mangalam Drugs And Organics Limited has informed the Exchange regarding Resignation of Ms. Anuradha Pandey as Company Secretary & Compliance Officer of the company w.e.f. March 29, 2026. · Management Changes
- Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest · Regulatory & Legal
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 10, 2026 for Shree Kishoriju Trading .... · Ownership Changes
- Mangalam Drugs And Organics Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Mangalam Drugs And Organics Limited has informed the Exchange about Change in Company Secretary/Compliance Officer · Management Changes
- Mangalam Drugs And Organics Limited has informed the Exchange regarding Outcome of Board Meeting held on March 26, 2026. · Board & Shareholder Meetings
- Mangalam Drugs And Organics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Ajay Ramniwas dhoot has submitted to the Exchange a copy of Disclosure pursuant to Regulations 31(1) and 31(2) of the SEBI (SAST) Regulations, 2011 by the promoter/Promoter group to the stock Exchanges for release of pledged shares. · Ownership Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹290 Cr over the trailing twelve months.
Market Cap
₹52 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-27.3%·
ROCE (5y median)
ROE -43.1% · margin -6.1%
Leverage
1.02·
Debt / Equity · moderate
Net debt ₹105 Cr
Revenue FY24→FY26
0.6×▼
Margin −16.7 pts
₹369 Cr → ₹232 Cr
Moves on a normal day
1.67%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/B#7/164
ROCE#174/183
ROE#168/171
Debt / Equity#160/171
EBITDA margin#151/165
Revenue growth#123/161
Profit growth#69/158
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Returns on capital -27.3%
#174 of 183 in Pharmaceuticals on the latest reported figures
Carries more debt than its peers — 1.02× equity
lower than 7% of its 171 Pharmaceuticals peers
Charts
How has the market priced it — with filings on the timeline?
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from MANGALAM DRUG & CHEM LTD's filed financials and exchange disclosures
What does MANGALAM DRUG & CHEM LTD do?
MANGALAM DRUG & CHEM LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MANGALAM.
Is MANGALAM DRUG & CHEM LTD profitable?
No. Over the trailing twelve months MANGALAM DRUG & CHEM LTD reported a net loss of ₹52 Cr on revenue of ₹290 Cr.
Does MANGALAM DRUG & CHEM LTD pay a dividend?
Not in the latest reported year — MANGALAM DRUG & CHEM LTD's dividend payout for FY26 was nil.
Is MANGALAM DRUG & CHEM LTD debt-free?
No. Debt stands at 1.02× equity, and it carries net debt of ₹105 Cr. That is lower than 7% of its 171 Pharmaceuticals peers.
How much does the MANGALAM DRUG & CHEM LTD share price move in a day?
On a typical session MANGALAM DRUG & CHEM LTD moves 1.67% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track MANGALAM DRUG & CHEM LTD's announcements?
Every NSE and BSE filing by MANGALAM DRUG & CHEM LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.